BBIO logo

BridgeBio Pharma (BBIO)

Profile

Full Name

BridgeBio Pharma, Inc.

Ticker Symbol

BBIO

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 27, 2019

Indexes

Not included

Website

http://bridgebio.com

Employees

725

Key Details

Price

$33.91(+4.95%)

Market cap

$6.45B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$221.90M(+2285.27% YoY)

Annual EPS

-$2.88(+27.09% YoY)

PE ratio

-

Next earnings date

May 2, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$33.91
BBIO price is $33.91

30-Day Relative Volume

0.72
BBIO 30-day relative volume is 0.72

Price Performance

Price Today change

+4.95%
BBIO price is up +4.95% today

Price YTD change

+23.58%
BBIO price is up +23.58% since January 1st

Price 1-year change

+19.57%
BBIO price is up +19.57% year-on-year

Price 3-year change

+213.11%
BBIO price is up +213.11% over the past 3 years

Price Range

Price All-time high

$73.50
BBIO price is currently -53.86% below its historical high of $73.50

Price 3-year low

$4.98
BBIO price is currently +580.92% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$6.45B
BBIO market capitalization is $6.45 billion

Market cap 3-year change

+303.22%
BBIO market capitalization is up +303.22% over the past 3 years

Market cap All-time high

$10.77B
BBIO market capitalization is currently -40.10% below its historical high of $10.77 billion

Market cap sector rank

90.63%
BBIO market capitalization is higher than 90.63% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1.64%
BBIO shares outstanding is up +1.64% year-on-year

Shares Outstanding 3-Year Change

+28.78%
BBIO shares outstanding is up +28.78% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.06
BBIO beta is 1.06

200-day SMA

$28.62
BBIO price is currently +18.48% above its 200-day simple moving average

50-day SMA

$33.60
BBIO price is currently +0.93% above its 50-day simple moving average

RSI

51.71
BBIO 14-day relative strength index is 51.71

Volume

0.72
BBIO 30-day relative volume is 0.72

ATR

$2.35
BBIO average true range is $2.35

10-day Historical Volatility

80.03%
BBIO 10-day historical volatility is 80.03%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$221.90M
BBIO annual revenue is $221.90 million

Revenue Analysts estimate

$232.97M
BBIO annual revenue is currently -4.75% lower than the consensus analysts' forecast

Revenue 1-year change

+2285.27%
BBIO annual revenue is up +2285.27% year-on-year

Revenue Sector rank

65.51%
BBIO annual revenue is higher than 65.51% of companies in Healthcare sector

EPS

EPS

-$2.88
BBIO annual earnings per share is -$2.88

EPS Analysts estimate

-$3.74
BBIO annual earnings per share is currently -23.01% lower than the consensus analysts' forecast

EPS 1-year change

+27.09%
BBIO annual earnings per share is up +27.09% year-on-year

EPS Sector rank

30.88%
BBIO annual earnings per share is higher than 30.88% of companies in Healthcare sector

Profit

Gross profit

$218.02M
BBIO annual gross profit is $218.02 million

Gross margin

98.25%
BBIO annual gross profit margin is 98.25%

Operating profit

-$577.37M
BBIO annual operating income is -$577.37 million

Operating margin

-260.19%
BBIO annual operating profit margin is -260.19%

Net income

-$535.76M
BBIO annual net profit is -$535.76 million

Net margin

-241.44%
BBIO annual net profit margin is -241.44%

Expenses

Total expenses

$799.27M
BBIO annual total expenses is $799.27 million

Operating expenses

$795.39M
BBIO annual total operating expenses is $795.39 million

Cost of goods sold

$3.88M
BBIO annual cost of goods sold is $3.88 million

Selling, general & administrative expenses

$288.93M
BBIO annual SGA is $288.93 million

Depreciation and amortization

$6.08M
BBIO annual depreciation & amortization is $6.08 million

Interest expense

$99.29M
BBIO annual interest expense is $99.29 million

Income tax

$1.15M
BBIO annual income tax is $1.15 million

EBIT & EBITDA

EBIT

-$442.90M
BBIO annual earnings before interest & taxes is -$442.90 million

EBITDA

-$436.83M
BBIO annual EBITDA is -$436.83 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$919.34M
BBIO annual total assets is $919.34 million

Non current assets

$198.65M
BBIO annual long term assets is $198.65 million

Current assets

$720.69M
BBIO annual total current assets is $720.69 million

Cash and cash equivalents

$681.10M
BBIO annual cash & cash equivalents is $681.10 million

Accounts receivable

$4.72M
BBIO annual accounts receivable is $4.72 million

Inventory

-
BBIO annual inventory value is unknown

Liabilities

Total liabilities

$2.38B
BBIO annual total liabilities is $2.38 billion

Long term liabilities

$2.22B
BBIO annual total long term liabilities is $2.22 billion

Current liabilities

$154.40M
BBIO annual total current liabilities is $154.40 million

Accounts payable

$9.62M
BBIO annual accounts payable is $9.62 million

Debt

Total debt

$1.73B
BBIO annual total debt is $1.73 billion

Total debt 1-year change

-0.53%
BBIO annual total debt is down -0.53% year-on-year

Long term debt

$1.73B
BBIO annual long term debt is $1.73 billion

Short term debt

$4.51M
BBIO annual short term debt is $4.51 million

Equity & Capital

Shareholders equity

-$1.47B
BBIO annual stockholders equity is -$1.47 billion

Book value

-$1.47B
BBIO annual book value is -$1.47 billion

Retained earnings

-$3.10B
BBIO annual retained earnings is -$3.10 billion

Working capital

$566.29M
BBIO annual working capital is $566.29 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$520.73M
BBIO annual cash flow from operations is -$520.73 million

Cash from operations 1-year change

+1.33%
BBIO annual cash flow from operations is up +1.33% year-on-year

Cash from investing

$60.78M
BBIO annual cash flow from investing activities is $60.78 million

Cash from investing 1-year change

+12.49%
BBIO annual cash flow from investing activities is up +12.49% year-on-year

Cash from financing

$748.46M
BBIO annual cash flow from financing activities is $748.46 million

Cash from financing 1-year change

+65.76%
BBIO annual cash flow from financing activities is up +65.76% year-on-year

CAPEX

CAPEX

$8.91M
BBIO annual capital expenditures is $8.91 million

CAPEX 1-year change

+582.08%
BBIO annual capital expenditures is up +582.08% year-on-year

Free Cash Flow

Free cash flow

-$529.63M
BBIO annual free cash flow is -$529.63 million

Free cash flow 1-year change

-0.11%
BBIO annual free cash flow is down -0.11% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

98.25%
BBIO annual gross profit margin is 98.25%

Operating margin

-260.19%
BBIO annual operating profit margin is -260.19%

Net margin

-241.44%
BBIO annual net profit margin is -241.44%

ROA & ROE

ROA

-73.11%
BBIO annual return on assets is -73.11%

ROE

36.50%
BBIO annual return on equity is 36.50%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
BBIO price to earnings ratio value is unknown

PE ratio Sector rank

-
BBIO price to earnings ratio is unknown

PB Ratio

PB ratio

-4.39
BBIO price to book ratio is -4.39

PB ratio Sector rank

4.19%
BBIO price to book ratio is higher than 4.19% of companies in Healthcare sector

PS Ratio

PS ratio

29.06
BBIO price to sales ratio is 29.06

PS ratio Sector rank

88.97%
BBIO price to sales ratio is higher than 88.97% of companies in Healthcare sector

Enterprise value

Enterprise value

$7.50B
BBIO enterprise value is $7.50 billion

Enterprise value Sector rank

90.52%
BBIO enterprise value is higher than 90.52% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-17.17
BBIO EV/EBITDA is -17.17

EV/EBITDA Sector rank

6.68%
BBIO EV/EBITDA is higher than 6.68% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

4.67
BBIO annual current ratio is 4.67

Quick ratio

-
BBIO annual quick ratio value is unknown

Leverage

Debt to equity

-1.17
BBIO annual debt to equity ratio is -1.17

Interest coverage ratio

-4.46
BBIO annual interest coverage ratio is -4.46

Risk & Stability

Piotroski F-Score

4
BBIO piotroski f-score is 4

Altman Z-Score

-3.70
BBIO altman z-score is -3.70

Analyst ratings

Recent major analysts updates

Mar 31, 25 Redburn Atlantic
Buy
Mar 24, 25 JP Morgan
Overweight
Feb 21, 25 Scotiabank
Sector Outperform
Feb 21, 25 Citigroup
Buy
Feb 21, 25 Cantor Fitzgerald
Overweight
Feb 13, 25 HC Wainwright & Co.
Buy
Feb 12, 25 Scotiabank
Sector Outperform
Dec 23, 24 Evercore ISI Group
Outperform
Dec 16, 24 HC Wainwright & Co.
Buy
Nov 25, 24 Scotiabank
Sector Outperform

Institutional Ownership

Similar stocks

WAY logo
Waystar Holding (WAY)
RVMD logo
Revolution Medicines (RVMD)
JAZZ logo
Jazz Pharmaceuticals (JAZZ)
TFX logo
Teleflex Incorporated (TFX)
BIO logo
Bio-Rad Laboratories (BIO)
RGEN logo
Repligen (RGEN)
STVN logo
Stevanato Group SpA (STVN)
LNTH logo
Lantheus Holdings (LNTH)
MDGL logo
Madrigal Pharmaceuticals (MDGL)
  • What is the ticker symbol for BridgeBio Pharma?
  • Does BridgeBio Pharma pay dividends?
  • What sector is BridgeBio Pharma in?
  • What industry is BridgeBio Pharma in?
  • What country is BridgeBio Pharma based in?
  • When did BridgeBio Pharma go public?
  • Is BridgeBio Pharma in the S&P 500?
  • Is BridgeBio Pharma in the NASDAQ 100?
  • Is BridgeBio Pharma in the Dow Jones?
  • When was BridgeBio Pharma's last earnings report?
  • When does BridgeBio Pharma report earnings?
  • Should I buy BridgeBio Pharma stock now?

What is the ticker symbol for BridgeBio Pharma?

The ticker symbol for BridgeBio Pharma is NASDAQ:BBIO

Does BridgeBio Pharma pay dividends?

No, BridgeBio Pharma does not pay dividends

What sector is BridgeBio Pharma in?

BridgeBio Pharma is in the Healthcare sector

What industry is BridgeBio Pharma in?

BridgeBio Pharma is in the Biotechnology industry

What country is BridgeBio Pharma based in?

BridgeBio Pharma is headquartered in United States

When did BridgeBio Pharma go public?

BridgeBio Pharma's initial public offering (IPO) was on June 27, 2019

Is BridgeBio Pharma in the S&P 500?

No, BridgeBio Pharma is not included in the S&P 500 index

Is BridgeBio Pharma in the NASDAQ 100?

No, BridgeBio Pharma is not included in the NASDAQ 100 index

Is BridgeBio Pharma in the Dow Jones?

No, BridgeBio Pharma is not included in the Dow Jones index

When was BridgeBio Pharma's last earnings report?

BridgeBio Pharma's most recent earnings report was on Feb 20, 2025

When does BridgeBio Pharma report earnings?

The next expected earnings date for BridgeBio Pharma is May 2, 2025

Should I buy BridgeBio Pharma stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page